Little in population health practice has received more scrutiny than mammography screening, and the relentless debate around breast cancer (BC) screening is unlikely to fade as the options of adjunct screening technologies increase. Yet none of the currently available adjunct breast imaging technologies seems as promising, or as feasible to implement on a large scale, as digital breast tomosynthesis (DBT), a pseudo–3-dimensional derivative technology of digital mammography (DM). In fact, this technology appears to be disseminating throughout the United States faster than the pace witnessed for DM in the preceding decade, with 50% of facilities in the Breast Cancer Surveillance Consortium now offering DBT.